Skip to main content
Erschienen in: Familial Cancer 2/2009

01.06.2009

Recurring MLH1 deleterious mutations in unrelated Chinese Lynch syndrome families in Singapore

verfasst von: Hui-Ling Yap, Wei-Shieng Chieng, Jasmine Rui-Chen Lim, Robert Seng-Cheong Lim, Ross Soo, Jiayi Guo, Soo-Chin Lee

Erschienen in: Familial Cancer | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Lynch syndrome is an autosomal dominant disorder due to mutations in DNA mismatch repair genes, causing young onset colorectal cancer and extra-colonic cancers such as endometrial and stomach cancers. We genotyped MLH1 and MSH2 in patients suspected to have Lynch syndrome and correlated patient clinical characteristics and family history with deleterious mutations. Eighty-five unrelated patients participated. Comprehensive sequencing was performed for MLH1 and MSH2, including all coding regions, splice-site junctions and promoter regions. Of the 29 different mutations found, 11 were deleterious, of which 10 were in MLH1 and 1 in MSH2. Three recurring MLH1 deleterious mutations were found in two unrelated Chinese patients each, and haplotype analysis suggested common ancestral origin for the recurring mutations and possible founder effect. Families with clinical diagnosis of HNPCC (i.e. family history which fulfills the Amsterdam I/II criteria) was the strongest predictor for finding a deleterious mutation, and stomach cancer was the most commonly reported extra-colonic cancer in families found with a deleterious MLH1 or MSH2 mutation. The observation of recurring deleterious MLH1 mutations in our study suggests possible founder effect and may have implications on genetic testing in Asia.
Literatur
1.
Zurück zum Zitat Seow A, Koh WP, Chia KS, Shi LM, Lee HP, Shanmugaratnam K (2004) Trends in cancer incidence in Singapore 1968–2002. Singapore cancer registry report no 6 Seow A, Koh WP, Chia KS, Shi LM, Lee HP, Shanmugaratnam K (2004) Trends in cancer incidence in Singapore 1968–2002. Singapore cancer registry report no 6
3.
Zurück zum Zitat Lynch HT, Smyrk T (1996) Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer 78(6):1149–1167. doi :10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.0.CO;2-5PubMedCrossRef Lynch HT, Smyrk T (1996) Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer 78(6):1149–1167. doi :10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.0.CO;2-5PubMedCrossRef
4.
Zurück zum Zitat Mecklin JP (1987) Frequency of hereditary colorectal carcinoma. Gastroenterology 93(5):1021–1025PubMed Mecklin JP (1987) Frequency of hereditary colorectal carcinoma. Gastroenterology 93(5):1021–1025PubMed
5.
Zurück zum Zitat Watson P, Lynch HT (1993) Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71(3):677–685. doi :10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#PubMedCrossRef Watson P, Lynch HT (1993) Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71(3):677–685. doi :10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#PubMedCrossRef
6.
Zurück zum Zitat Mecklin JP, Jarvinen HJ (1991) Tumor spectrum in cancer family syndrome (hereditary nonpolyposis colorectal cancer). Cancer 68(5):1109–1112. doi :10.1002/1097-0142(19910901)68:5<1109::AID-CNCR2820680535>3.0.CO;2-SPubMedCrossRef Mecklin JP, Jarvinen HJ (1991) Tumor spectrum in cancer family syndrome (hereditary nonpolyposis colorectal cancer). Cancer 68(5):1109–1112. doi :10.1002/1097-0142(19910901)68:5<1109::AID-CNCR2820680535>3.0.CO;2-SPubMedCrossRef
9.
Zurück zum Zitat Bronner CE, Baker SM, Morrison PT et al (1994) Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368(6468):258–261. doi:10.1038/368258a0 PubMedCrossRef Bronner CE, Baker SM, Morrison PT et al (1994) Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368(6468):258–261. doi:10.​1038/​368258a0 PubMedCrossRef
11.
Zurück zum Zitat Vasen HF, Mecklin JP, Khan PM et al (1991) The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 34(5):424–425. doi:10.1007/BF02053699 PubMedCrossRef Vasen HF, Mecklin JP, Khan PM et al (1991) The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 34(5):424–425. doi:10.​1007/​BF02053699 PubMedCrossRef
12.
Zurück zum Zitat Park JG, Vasen HF, Park KJ et al (1999) Suspected hereditary nonpolyposis colorectal cancer: international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC) criteria and results of genetic diagnosis. Dis Colon Rectum 42(6):710–715. doi:10.1007/BF02236922 (discussion 5–6)PubMedCrossRef Park JG, Vasen HF, Park KJ et al (1999) Suspected hereditary nonpolyposis colorectal cancer: international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC) criteria and results of genetic diagnosis. Dis Colon Rectum 42(6):710–715. doi:10.​1007/​BF02236922 (discussion 5–6)PubMedCrossRef
13.
Zurück zum Zitat Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268PubMedCrossRef Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268PubMedCrossRef
15.
Zurück zum Zitat Wang XL, Yuan Y, Zhang SZ et al (2006) Clinical and genetic characteristics of Chinese hereditary nonpolyposis colorectal cancer families. World J Gastroenterol 12(25):4074–4077PubMed Wang XL, Yuan Y, Zhang SZ et al (2006) Clinical and genetic characteristics of Chinese hereditary nonpolyposis colorectal cancer families. World J Gastroenterol 12(25):4074–4077PubMed
16.
Zurück zum Zitat Park JG, Park YJ, Wijnen JT et al (1999) Gene–environment interaction in hereditary nonpolyposis colorectal cancer with implications for diagnosis and genetic testing. Int J Cancer 82(4):516–519. doi :10.1002/(SICI)1097-0215(19990812)82:4<516::AID-IJC8>3.0.CO;2-UPubMedCrossRef Park JG, Park YJ, Wijnen JT et al (1999) Gene–environment interaction in hereditary nonpolyposis colorectal cancer with implications for diagnosis and genetic testing. Int J Cancer 82(4):516–519. doi :10.1002/(SICI)1097-0215(19990812)82:4<516::AID-IJC8>3.0.CO;2-UPubMedCrossRef
17.
Zurück zum Zitat Moisio AL, Sistonen P, Weissenbach J et al (1996) Age and origin of two common MLH1 mutations predisposing to hereditary colon cancer. Am J Hum Genet 59(6):1243–1251PubMed Moisio AL, Sistonen P, Weissenbach J et al (1996) Age and origin of two common MLH1 mutations predisposing to hereditary colon cancer. Am J Hum Genet 59(6):1243–1251PubMed
18.
19.
Zurück zum Zitat Boland CR, Thibodeau SN, Hamilton SR et al (1998) A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58(22):5248–5257PubMed Boland CR, Thibodeau SN, Hamilton SR et al (1998) A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58(22):5248–5257PubMed
20.
Zurück zum Zitat Berg KD, Glaser CL, Thompson RE et al (2000) Detection of microsatellite instability by fluorescence multiplex polymerase chain reaction. J Mol Diagn 2(1):20–28PubMed Berg KD, Glaser CL, Thompson RE et al (2000) Detection of microsatellite instability by fluorescence multiplex polymerase chain reaction. J Mol Diagn 2(1):20–28PubMed
23.
24.
Zurück zum Zitat Chan TL, Chan YW, Ho JW et al (2004) MSH2 c.1452-1455delAATG is a founder mutation and an important cause of hereditary nonpolyposis colorectal cancer in the southern Chinese population. Am J Hum Genet 74(5):1035–1042. doi:10.1086/383591 PubMedCrossRef Chan TL, Chan YW, Ho JW et al (2004) MSH2 c.1452-1455delAATG is a founder mutation and an important cause of hereditary nonpolyposis colorectal cancer in the southern Chinese population. Am J Hum Genet 74(5):1035–1042. doi:10.​1086/​383591 PubMedCrossRef
28.
Zurück zum Zitat Liu SR, Zhao B, Wang ZJ et al (2004) Clinical features and mismatch repair gene mutation screening in Chinese patients with hereditary nonpolyposis colorectal carcinoma. World J Gastroenterol 10(18):2647–2651PubMed Liu SR, Zhao B, Wang ZJ et al (2004) Clinical features and mismatch repair gene mutation screening in Chinese patients with hereditary nonpolyposis colorectal carcinoma. World J Gastroenterol 10(18):2647–2651PubMed
29.
Zurück zum Zitat Bai YQ, Akiyama Y, Nagasaki H et al (1999) Predominant germ-line mutation of the hMSH2 gene in Japanese hereditary non-polyposis colorectal cancer kindreds. Int J Cancer 82(4):512–515. doi :10.1002/(SICI)1097-0215(19990812)82:4<512::AID-IJC7>3.0.CO;2-8PubMedCrossRef Bai YQ, Akiyama Y, Nagasaki H et al (1999) Predominant germ-line mutation of the hMSH2 gene in Japanese hereditary non-polyposis colorectal cancer kindreds. Int J Cancer 82(4):512–515. doi :10.1002/(SICI)1097-0215(19990812)82:4<512::AID-IJC7>3.0.CO;2-8PubMedCrossRef
30.
32.
Zurück zum Zitat Wijnen J, Khan PM, Vasen H et al (1997) Hereditary nonpolyposis colorectal cancer families not complying with the Amsterdam criteria show extremely low frequency of mismatch-repair-gene mutations. Am J Hum Genet 61(2):329–335. doi:10.1086/514847 PubMedCrossRef Wijnen J, Khan PM, Vasen H et al (1997) Hereditary nonpolyposis colorectal cancer families not complying with the Amsterdam criteria show extremely low frequency of mismatch-repair-gene mutations. Am J Hum Genet 61(2):329–335. doi:10.​1086/​514847 PubMedCrossRef
33.
Zurück zum Zitat Feng BJ, Huang W, Shugart YY et al (2002) Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 31(4):395–399PubMed Feng BJ, Huang W, Shugart YY et al (2002) Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 31(4):395–399PubMed
34.
Zurück zum Zitat Baudhuin LM, Burgart LJ, Leontovich O et al (2005) Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer 4(3):255–265. doi:10.1007/s10689-004-1447-6 PubMedCrossRef Baudhuin LM, Burgart LJ, Leontovich O et al (2005) Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer 4(3):255–265. doi:10.​1007/​s10689-004-1447-6 PubMedCrossRef
36.
Zurück zum Zitat Plaschke J, Engel C, Kruger S et al (2004) Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German hereditary nonpolyposis colorectal cancer consortium. J Clin Oncol 22(22):4486–4494. doi:10.1200/JCO.2004.02.033 PubMedCrossRef Plaschke J, Engel C, Kruger S et al (2004) Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German hereditary nonpolyposis colorectal cancer consortium. J Clin Oncol 22(22):4486–4494. doi:10.​1200/​JCO.​2004.​02.​033 PubMedCrossRef
Metadaten
Titel
Recurring MLH1 deleterious mutations in unrelated Chinese Lynch syndrome families in Singapore
verfasst von
Hui-Ling Yap
Wei-Shieng Chieng
Jasmine Rui-Chen Lim
Robert Seng-Cheong Lim
Ross Soo
Jiayi Guo
Soo-Chin Lee
Publikationsdatum
01.06.2009
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 2/2009
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-008-9209-5

Weitere Artikel der Ausgabe 2/2009

Familial Cancer 2/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.